Natural Products as Pharmaceuticals and Sources for Lead Structures

The Practice of Medicinal Chemistry: Fourth Edition

Volumn , Issue , 2015, Pages 101-139

  Newman, David J ^a   Cragg, Gordon M ^a   Kingston, David G I ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Cancer; Genomics; Infectious Disease; Metabolomics; Natural Products

Indexed keywords

EID: 84939839223     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-417205-0.00005-5     Document Type: Chapter

References (301)

1. Borchardt J.K. The beginnings of drug therapy: ancient mesopotamian medicine. Drug News Perspect 2002, 15:187-192.
2. Huang K.C. The pharmacology of chinese herbs 1999, CRC Press, Boca Raton, FL. 2nd ed.
3. Kapoor L.D. CRC handbook of ayurvedic medicinal plants 1990, CRC Press, Boca Raton, FL.
4. Dev S. Ancient-modern concordance in ayurvedic plants: some examples. Environ Health Perspect 1999, 107:783-789.
5. Moerman D.E. Medicinal plants of Native America 1986, University of Michigan Museum of Anthropology, Ann Arbor, MI.
6. Johnson T. CRC Ethnobotany desk reference 1999, CRC Press, Boca Raton, FL.
7. Farnsworth N.R. The role of ethnopharmacology in drug development. Bioactive compounds from plants 1990, 2-21. Wiley, Chichester. D.J. Chadwick, J. Marsh (Eds.).
8. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012, 75:311-335.
9. Newman D.J., Cragg G.M., Snader K.M. The influence of natural products upon drug discovery. Nat Prod Rep 2000, 17:215-234.
10. US Food and Drug Administration. Summary of novel new drugs. Available from: 2013. http://www.fda.gov/downloads/drugs/developmentapprovalprocess/druginnovation/ucm381803.pdf.
11. Rouhi M. Rediscovering natural products. Chem Eng News 2003, 81:77-91.
12. Borman S. Improving efficiency. Chem Eng News 2006, 84:56-78.
13. Li J.W., Vederas J.C. Drug discovery and natural products: end of an era or an endless frontier?. Science 2009, 325:161-165.
14. Nicolaou K.C. Advancing the drug discovery and development process. Angew Chem Int Ed 2014, 53:9128-9140.
15. Haslam E. Secondary metabolism: fact and fiction. Nat Prod Rep 1986, 3:217-249.
16. Williams D.H., Stone M.J., Hauck P.R., Rahman S.K. Why are secondary metabolites (natural products) biosynthesized?. J Nat Prod 1989, 52:1189-1208.
17. Harborne J.B. Role of secondary metabolites in chemical defence mechanisms in plants. Bioactive compounds from plants 1990, 126-139. Wiley, Chichester. D.J. Chadwick, J. Marsh (Eds.).
18. Schröeder F.C., Farmer J.J., Attygalle A.B., Smedley S.R., Eisner T., Meinwald J. Combinatorial chemistry in insects: a library of defensive macrocyclic polyamines. Science 1998, 281:428-431.
19. Han T.S., Teichert R.W., Olivera B.M., Bulaj G. Conus venoms: a rich source of peptide-based therapeutics. Curr Pharm Des 2008, 14:2462-2479.
20. Lewis R.J., Dutertre S., Vetter I., Christie M.J. Conus venom peptide pharmacology. Pharmacol Rev 2012, 64:259-298.
21. Wallace M.S. Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain. Expert Rev Neurother 2006, 6:1423-1428.
22. Czaran T.L., Hoekstra R.F., Pagie L. Chemical warfare between microbes promotes biodiversity. Proc Natl Acad Sci U S A 2002, 99:786-790.
23. Bais H.P., Vepachedu R., Gilroy S., Callaway R.M., Vivanco J.M. Allelopathy and exotic plant invasion: from molecules and genes to species interactions. Science 2003, 301:1377-1380.
24. Li Z.H., Wang Q., Ruan X., Pan C.D., Jiang A.D. Phenolics and plant allelopathy. Molecules 2010, 15:8933-8952.
25. Everts S. Bacterial conversations. Chem Eng News 2006, 84:17-26.
26. Rice S.A., McDougald D., Kumar N., Kjelleberg S. The use of quorum-sensing blockers as therapeutic agents for the control of biofilm-associated infections. Curr Opin Investig Drugs 2005, 6:178-184.
27. Njoroge J., Sperandio V. Jamming bacterial communication: new approaches for the treatment of infectious diseases. EMBO Mol Med 2009, 1:201-210.
28. Sintim H.O., Smith J.A., Wang J., Nakayama S., Yan L. Paradigm shift in discovering next-generation anti-infective agents: targeting quorum sensing, c-di-GMP signaling and biofilm formation in bacteria with small molecules. Future Med Chem 2010, 6:1005-1035.
29. Roy V., Adams B.L., Bentley W.E. Developing next generation antimicrobials by intercepting AI-2 mediated quorum sensing. Enzyme Microb Technol 2011, 49:113-123.
30. Bhardwaj A.K., Vinothkumar K., Rajpara N. Bacterial quorum sensing inhibitors: attractive alternatives for control of infectious pathogens showing multiple drug resistance. Recent Pat Antiinfect Drug Discov 2013, 8:68-83.
31. Scutera S., Zucca M., Savoia D. Novel approaches for the design and discovery of quorum-sensing inhibitors. Expert Opin Drug Discov 2014, 9:353-366.
32. Figueroa M., Jarmusch A.K., Raja H.A., El-Elimat T., Kavanaugh J.S., Horswill A.R., et al. Polyhydroxyanthraquinones as quorum sensing inhiitors from the guttates of Penicillium restrictum and their analysis by desorption electrospray ionization mass spectrometry. J Nat Prod 2014, 77:1351-1358.
33. Melander R.J., Minvielle M.J., Melander C. Controlling bacterial behavoir with indole-containing natural products and derivatives. Tetrahedron 2014, 70:6363-6372.
34. Fletcher M.H., Jennings M.C., Wuest W.M. Draining the moat: disrupting bacterial biofilms with natural products. Tetrahedron 2014, 70:6373-6383.
35. Meijer L. Le cycle de division cellulaire et sa regulation [The cycle of cellular division and its regulation]. Oncologie 2003, 5:311-326. [in French].
36. Klekota J., Brauner E., Roth F.P., Schreiber S.L. Using high-throughput screening data to discriminate compounds with single-target effects from those with side effects. J Chem Inf Model 2006, 46:1549-1562.
37. Liu B., Li S., Hu J. Technological advances in high-throughput screening. Am J Pharmacogenomics 2004, 4:263-276.
38. Mullin R. Drug discovery. Chem Eng News 2004, 82:23-32.
39. Wang J., Soisson S.M., Young K., Shoop W., Kodali S., Galgoci A., et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 2006, 441:358-361.
40. Ghosh A.K., Xi K. Platensimycin and platencin. Natural products in medicinal chemistry 2014, 271-300. Wiley-VCH Verlag, Switzerland. S. Hanessian (Ed.).
41. Cragg G.M., Katz F., Newman D.J., Rosenthal J. The impact of the United Nations convention on biological diversity on natural products research. Nat Prod Rep 2012, 29:1407-1423.
42. ten Kate K., Wells A. Benefit-sharing case study. The access and benefit-sharing policies of the United States National Cancer Institute: a comparative account of the discovery and development of the drugs calanolide and topotecan. Submission to the executive secretary of the convention on biological diversity 1998, The Royal Botanic Gardens, Kew, UK.
43. Rosenthal J.P. Drug discovery, economic development, and conservation: the international cooperative biodiversity groups. Pharm Biol 1999, 37:5.
44. ten Kate K., Laird S.A. The commercial use of biodiversity: access to genetic resources and benefit-sharing 1999, Earthscan Publications, Ltd, London, UK.
45. Balick M.J. Ethnobotany and the identification of therapeutic agents from the rainforest. Bioactive compounds from plants 1990, 22-39. Wiley, Chichester. D.J. Chadwick, J. Marsh (Eds.).
46. Cox P.A. Ethnopharmacology and the search for new drugs. Bioactive compounds from plants 1990, 40-55. Wiley, Chichester. D.J. Chadwick, J. Marsh (Eds.).
47. Plotkin M.J. Conservation, ethnobotany, and the search for new jungle medicines: pharmacognosy comes of age...again. Pharmacotherapy 1988, 8:257-262.
48. Balandrin M.F., Kinghorn A.D., Farnsworth N.R. Plant-derived natural products in drug discovery and development: an overview. Human medicinal agents from plants 1993, 2-12. Amer Chem Soc, Washington, DC. A.D. Kinghorn, M.F. Balandrin (Eds.).
49. Raskin I., Ribnicky D.M., Komarnytsky S., Ilic N., Poulev A., Borisjuk N., et al. Plants and human health in the twenty-first century. Trends Biotechnol 2002, 20:522-531.
50. Poulev A., O'Neal J.M., Logendra S., Pouleva R.B., Timeva V., Garvey A.S., et al. Elicitation, a new window into plant chemodiversity and phytochemical drug discovery. J Med Chem 2003, 2542-2547.
51. McCoy E., O'Connor S.E. Directed biosynthesis of alkaloid analogs in the medicinal plant Catharanthus roseus. J Am Chem Soc 2006, 128:14276-14277.
52. Newman D.J., Cragg G.M. Marine natural products and related compounds in clinical and advanced preclinical trials. J Nat Prod 2004, 67:1216-1238.
53. Newman D.J., Hill R.T. New drugs from marine microbes: the tide is turning. J Ind Microbiol Biotechnol 2006, 33:539-544.
54. Shendure J., Ji H. Next-generation DNA sequencing. Nat Biotech 2008, 26:1135-1145.
55. Prüfer K., Racimo F., Patterson N., Jay F., Sankararaman S., Sawyer S., et al. The complete genome sequence of a Neanderthal from the Altai Mountains. Nature 2014, 505:43-49.
56. Wu D., Hugenholtz P., Mavromatis K., Pukall R., Dalin E., Ivanova N.N., et al. A phylogeny-driven genomic encyclopaedia of Bacteria and Archaea. Nature 2009, 462:1056-1060.
57. Birren B.W., Clifton S.W., Highlander S.K., Nelson K.E., Petrosino J.F., Sodergren E., et al. A catalog of reference genomes from the human microbiome. Science 2010, 328:994-999.
58. Smith M.I., Turpin W., Tyler A.D., Silverberg M.S., Croitoru K. Microbiome analysis: from technical advances to biological relevance. F1000Prime 2014, 6:51.
59. Ohnishi Y., Ishikawa J., Hara H., Suzuki H., Ikenoya M., Ikeda H., et al. Genome sequence of the streptomycin-producing microorganism Streptomyces griseus IFO 13350. J Bact 2008, 190:4050-4060.
60. von Döhren H. A survey of nonribosomal peptide synthetase (NRPS) genes in Aspergillus nidulans. Fungal Genet Biol 2009, 46:S45-S52.
61. Sanchez J.F., Somoza A.D., Keller N.P., Wang C.C.C. Advances in Aspergillus secondary metabolite research in the post-genomic era. Nat Prod Rep 2012, 29:351-371.
62. Jain S., Keller N. Insights to fungal biology through LaeA sleuthing. Fungal Biol Rev 2013, 27:51-59.
63. Lim F.Y., Keller N.P. Spatial and temporal control of fungal natural product synthesis. Nat Prod Rep 2014, 31:1277-1286.
64. Williams R.B., Henrikson J.C., Hoover A.R., Lee A.E., Cichewicz R.H. Epigenetic remodeling of the fungal secondary metabolome. Org Biomol Chem 2008, 7:435-438.
65. Cichewicz R.H. Epigenome manipulation as a pathway to new natural product scaffolds and their congeners. Nat Prod Rep 2010, 27:11-22.
66. Zuck K.M., Shipley S., Newman D.J. Induced production of N-formyl alkaloids from Aspergillus fumigatus by co-culture with Streptomyces peucetius. J Nat Prod 2011, 74:1653-1657.
67. Handelsman J., Rondon M.R., Brady S.F., Clardy J., Goodman R.M. Molecular biological access to the chemistry of unknown soil microbes: a new frontier for natural products. Chem Biol 1998, 5:R245-R249.
68. Nováková J., Farkašovský M. Bioprospecting microbial metagenome for natural products. Biologia 2013, 68:1079-1086.
69. Persidis A. Extremophiles. Nat Biotechnol 1998, 16:593-594.
70. Abe F., Horikoshi K. The biotechnological potential of piezophiles. Trends Biotechnol 2001, 19:102-108.
71. Rossi M., Ciaramella M., Cannio R., Pisani F.M., Moracci M., Bartolucci S. Extremophiles 2002. J Bacteriol 2003, 185:3683-3689.
72. Amato A. Microbes live near undersea CO2 lake. Chem Eng News 2006, 84:14.
73. Short P.L. New Zealand plays to its strengths. Chem Eng News 2007, 85:20-21.
74. Cavicchioli R., Siddiqui K.S., Andrews D., Sowers K.R. Low-temperature extremophiles and their applications. Curr Opin Biotechnol 2002, 13:253-261.
75. Johnson D.B., Hallberg K.B. The microbiology of acidic mine waters. Res Microbiol 2003, 154:466-473.
76. Stierle A.A., Stierle D.B., Kemp K. Novel sesquiterpenoid matrix metalloproteinase-3 inhibitors from an acid mine waste extremophile. J Nat Prod 2004, 67:1392-1395.
77. Stierle D.B., Stierle A.A., Hobbs D., Stokken J., Clardy J. Berkeleydione and berkeleytrione, new bioactive metabolites from an acid mine organism. Org Lett 2004, 6:1049-1052.
78. Stierle A.A., Stierle D.B. Bioprospecting in the Berkeley pit: the use of signal transduction enzyme inhibition assays to isolate bioactive secondary metabolites from the extremophilic fungi of an acid mine waste lake. Stud Nat Prod Chem 2013, 39:1-45.
79. Arto T., Mendoza A., Fañanás F.J., Rodríguez F. (-)-Berkelic acid: lessons learned from our investigations on a scalable total synthesis. Strategies Tactics Org Synth 2014, 10:33-50.
80. Niu S., Liu D., Hu X., Proksch P., Shao H., Lin W. Spiromastixones A-O, antibacterial chlorodepsidones from a deep-sea-derived Spiromastix sp. fungus. J Nat Prod 2014, 77:1021-1030.
81. Liu J.-T., Lu X.-L., Liu X.-Y., Gao Y., Jiao B.-H., Zheng H. Bioactive natural products from the Antarctic and Arctic organisms. Mini-Revs Med Chem 2013, 13:617-626.
82. Mosey R.A., Floreancig P.E. Isolation, biological activity, synthesis, and medicinal chemistry of the pederin/mycalamide family of natural products. Nat Prod Rep 2012, 29:980-995.
83. Skropeta D., Wei L. Recent advances in deep-sea natural products. Nat Prod Rep 2014, 31:999-1025.
84. Strobel G., Daisy B. Bioprospecting for microbial endophytes and their natural products. Microbiol Mol Biol Rev 2003, 67:491-502.
85. Strobel G., Daisy B., Castillo U., Harper J. Natural products from endophytic microorganisms. J Nat Prod 2004, 67:257-268.
86. Stierle A., Strobel G., Stierle D. Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew. Science 1993, 260:214-216.
87. Li J.-Y., Sidhu R.S., Bollon A., Strobel G.A. Stimulation of taxol production in liquid cultures of Pestalotiopsis microspora. Mycolog Res 1998, 102:461-464.
88. Eyberger A.L., Dondapati R., Porter J.R. Endophyte fungal Isolates from Podophyllum peltatum produce podophyllotoxin. J Nat Prod 2006, 69:1121-1124.
89. Puri S.C., Nazir A., Chawla R., Arora R., Riyaz-ul-Hasan S., Amna T., et al. The endophytic fungus Trametes hirsuta as a novel alternative source of podophyllotoxin and related tetralin lignans. J Biotech 2006, 122:494-510.
90. Amna T., Puri S.C., Verma V., Sharma J.P., Khajuria R.K., Musarrat J., et al. Bioreactor studies on the endophytic fungus Entrophosphora infrequens for the production of an anticancer alkaloid camptothecin. Can J Microbiol 2006, 52:189-196.
91. Puri S.C., Verma V., Amna T., Qazi G.N., Spiteller M. An endophytic fungus from Nothapodytes foetida that produces camptothecin. J Nat Prod 2005, 68:1717-1719.
92. Guo B., Li H., Zhang L. Isolation of a fungus producing vinblastine. J Yunnan Univ 1998, 20:214-215.
93. Zhang L.Q., Guo B., Li H., Zeng S., Shao H., Gu S., et al. Preliminary study on the isolation of endophytic fungus of Catharanthus roseus and its fermentation to produce products of therapeutic value. Zhong Cao Yao (Chinese Tradit Herb Drugs) 2000, 31:805-807.
94. Yang X., Zhang L., Guo B., Guo S. Preliminary study of a vincristine-producing endophytic fungus isolated from leaves of Catharanthus roseus. Zhong Cao Yao (Chinese Tradit Herb Drugs) 2004, 35:79-81.
95. Chandra S. Endophytic fungi: novel sources of anticancer lead molecules. App Microbiol Biotechnol 2012, 95:47-59.
96. Kusari S., Hertweck C., Spiteller M. Chemical ecology of endophytic fungi: origins of secondary metabolites. Chem Biol 2012, 19:792-798.
97. Grum D.S., Cook D., Baucom D., Mott I.W., Gardner D.R., Creamer R., et al. Production of the alkaloid swainsonine by a fungal endophyte in the host Swainsona canescens. J Nat Prod 2013, 76:1984-1988.
98. Cook D., Gardner D.R., Pfister J.A. Swainsonine-containing plants and their relationship to endophytic fungi. J Agric Food Chem 2014, 62:7326-7334.
99. Lopanik N.B., Shields J.A., Buchholz T.J., Rath C.M., Hothersall J., Haygood M.G., et al. In vivo and in vitro trans-acylation by bryP, the putative bryostatin pathway acyltransferase derived from an uncultured marine symbiont. Chem Biol 2008, 15:1175-1186.
100. Zheng L., Li G., Wang X., Pan W., Li L., Hua L., et al. Nematicidal endophytic bacteria obtained from plants. Ann Microbiol 2008, 58:569-572.
101. Tiwari R., Kalra A., Darokar M.P., Chandra M., Aggarwal N., Singh A.K., et al. Endophytic bacteria from Ocimum sanctum and their yield enhancing capabilities. Curr Microbiol 2010, 60:167-171.
102. Lu C., Shen Y. A novel ansamycin, naphthomycin K from Streptomyces sp. J Antibiot 2007, 60:649-653.
103. Igarashi Y., Yanase S., Sugimoto K., Enomoto M., Miyanaga S., Trujillo M.E., et al. Lupinacidin C, an inhibitor of tumor cell invasion from Micromonospora lupini. J Nat Prod 2011, 74:862-865.
104. Kupchan S.M., Komoda Y., Court W.A., Thomas G.J., Smith R.M., Karim A., et al. Tumor inhibitors. LXXIII. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc 1972, 94:1354-1356.
105. Higashide E., Asai M., Ootsu K., Tanida S., Kozai Y., Hasegawa T., et al. Ansamitocin, a group of novel maytansinoid antibiotics with antitumour properties from Nocardia. Nature 1977, 270:721-722.
106. Wings S., Müller H., Berg G., Lamshöft M., Leistner E. A study of the bacterial community in the root system of the maytansine containing plant Putterlickia verrucosa. Phytochemistry 2013, 91:158-164.
107. Bandara W.M.M.S., Seneviratne G., Kulasooriya S.A. Interactions among endophytic bacteria and fungi; effects and potential. J Biosci 2006, 31:645-650.
108. Nützmann H.-W., Reyes-Dominguez Y., Scherlach K., Schroeckh V., Horn F., et al. Bacteria-induced natural product formation in the fungus Aspergillus nidulans requires Saga/Ada-mediated histone acetylation. Proc Nat Acad Sci U S A 2011, 108:14282-14287.
109. Partida-Martinez L.P., Hertweck C. Pathogenic fungus harbours endosymbiotic bacteria for toxin production. Nature 2005, 437:884-888.
110. Partida-Martinez L.P., Monajembashi S., Greulich K.-O., Hertweck C. Endosymbiont-dependent host reproduction maintains bacterial-fungal mutualism. Curr Biol 2007, 17:773-777.
111. Scherlach K., Busch B., Lackner G., Paszkowski U., Hertweck C. Symbiotic cooperation in the biosynthesis of a phytotoxin. Angew Chem Int Ed 2012, 124:9753-9756.
112. Lundberg D.S., Lebeis S.L., Paredes S.H., Yourstone S., Gehring J., Malfatti S., et al. Defining the core Arabidopsis thaliana root microbiome. Nature 2012, 488:86-90.
113. Bulgarelli D., Rott M., Schlaeppi K., Ver Loren van Themaat E., Ahmadinejad N., Assenza F., et al. Revealing structure and assembly cues for Arabidopsis root-inhabiting bacterial microbiota. Nature 2012, 488:91-95.
114. Feling R.H., Buchanan G.O., Mincer T.J., Kauffman C.A., Jensen P.R., Fenical W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew Chem Int Ed 2003, 42:355-357.
115. Udwary D.W., Zeigler L., Asolkar R.N., Singan V., Lapidus A., Fenical W., et al. Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinispora tropica. Proc Natl Acad Sci U S A 2007, 104:10376-10381.
116. Lane A.L., Moore B.S. A sea of biosynthesis: marine natural products meet the molecular age. Nat Prod Rep 2011, 28:411-428.
117. Eustáquio A.S., O'Hagan D., Moore B.S. Engineering fluorometabolite production: fluorinase expression in Salinispora tropica yields fluorosalinosporamide. J Nat Prod 2010, 73:378-382.
118. Tsukimoto M., Nagaoka M., Shishido Y., Fujimoto J., Nishisaka F., Matsumoto S., et al. Bacterial production of the tunicate-derived antitumor cyclic depsipeptide didemnin B. J Nat Prod 2011, 74:2329-2331.
119. Shi B.H., Arunpairojana V., Palakawong S., Yokota A. Tistrella mobilis gen. nov., sp. nov., a novel polyhydroxyalkanoate-producing bacterium belonging to alpha-Proteobacteria. J Gen Appl Microbiol 2002, 48:335-343.
120. Zhang D.-C., Liu H.-C., Zhou Y.-G., Shinner F., Margesin R. Tistrella bauzanensis sp. nov., isolated from soil. Int J Sys Evol Microbiol 2011, 61:2227-2230.
121. Xu Y., Kersten R.D., Nam S.-J., Lu L., Al-Suwailem A.M., Zheng H., et al. Bacterial biosynthesis and maturation of the didemnin anti-cancer agents. J Am Chem Soc 2012, 134:8625-8632.
122. Hoehler T.M., Jorgensen B.B. Microbial life under extreme energy limitation. Nat Rev Microbiol 2013, 11:83-93.
123. Piel J. Metabolites from symbiotic bacteria. Nat Prod Rep 2004, 21:519-538.
124. Piel J., Hofer I., Hui D. Evidence for a symbiosis island involved in horizontal acquisition of pederin biosynthetic capabilities by the bacterial symbiont of Paederus fuscipes beetles. J Bacteriol 2004, 186:1280-1286.
125. Piel J., Butzke D., Fusetani N., Hui D., Platzer M., Wen G., et al. Exploring the chemistry of uncultivated bacterial symbionts: antitumor polyketides of the pederin family. J Nat Prod 2005, 68:472-479.
126. Giddings L.-A., Newman D.J. Microbial natural products: molecular blueprints for antitumor drugs. J Ind Microbiol Biotechnol 2013, 40:1181-1210.
127. Radjasa O.K., Vaske Y.M., Navarro G., Vervoort H.C., Tenney K., Linington R.G., et al. Highlights of marine invertebrate-derived biosynthetic products: their biomedical potential and possible production by microbial associants. Bioorg Med Chem 2011, 19:6658-6674.
128. Still P.C., Johnson T.A., Theodore C.M., Loveridge S.T., Crews P. Scrutinizing the scaffolds of marine biosynthetics from different source organisms: gram-negative cultured bacterial products enter center stage. J Nat Prod 2014, 77:690-702.
129. Wilson M.C., Mori T., Rückert C., Uria A.R., Helf M.J., Takada K., et al. An environmental bacterial taxon with a large and distinct metabolic repertoire. Nature 2014, 506:58-62.
130. Wakimoto T., Egami Y., Nakashima Y., Mori T., Awakawa T., Ito T., et al. Calyculin biogenesis from a pyrophosphate protoxin produced by a sponge symbiont. Nat Chem Biol 2014, 10:648-655.
131. Rocha-Martin J., Harrington C., Dobson A.D.W., O'Gara F. Emerging strategies and integrated systems microbiology technologies for biodiscovery of marine bioactive compounds. Mar Drugs 2014, 12:3516-3559.
132. Thomas M.G., Bixby K.A., Shen B. Combinatorial biosynthesis of anticancer natural molecules. Anticancer agents from natural products 2005, 519-552. Taylor & Francis, Boca Raton, FL. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
133. Van Lanen S.G., Shen B. Combinatorial biosynthesis of anticancer natural products. Anticancer agents from natural products 2012, 2012:671-698. Taylor & Francis, Boca Raton, FL. 2nd ed.
134. Bachmann B.O., Van Lanen S.G., Baltz R.H. Microbial genome mining for accelerated natural products discovery: is a renaissance in the making?. J Ind Microbiol Biotechnol 2014, 41:175-184.
135. Mahoney K.P.P., Smith D.R.M., Bogosyan E.J.A., Goss R.J.M. Access to high value natural and unnatural products through hyphenating chemical synthesis and biosynthesis. Synthesis 2014, 46:2122-2132.
136. McCloud T.G. High throughput extraction of plant, marine and fungal specimens for preservation of biologically active molecules. Molecules 2010, 15:4526-4563.
137. Beutler J.A., McKee T.C., Fuller R.W., Tischler M., Cardellina J.H., McCloud T.G., et al. Frequent occurrence of HIV-inhibitory sulfated polysaccharides in marine invertebrates. Antiviral Chem Chemother 1993, 3:167-172.
138. Cardellina J.H., Munro M.H.G., Fuller R.W., Manfredi K.P., McKee T.C., Tischler M., et al. A chemical-screening strategy for the dereplication and prioritization of HIV-inhibitory aqueous natural-products extracts. J Nat Prod 1993, 56:1123-1129.
139. Boyd M.R., Paull K.D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 1995, 34:91-109.
140. Developmental Theraputics Program. 2014. http://dtp.nci.nih.gov/.
141. Johnson R.K., Bartus H.F., Hofmann G.A., Bartus J.O., Mong S.-M., Faucette L.F., et al. Discovery of new DNA-reactive drugs. In vitro and in vivo models for detection of new antitumor drugs 1986, 1986:15-26. University of Tokyo Press, Tokyo.
142. Hassig C.A., Zeng F.-Y., Kung P., Kiankarimi M., Kim S., Diaz P.W., et al. Ultra high throughput screening of natural product extracts to identify pro-apoptotic inhibitors of Bcl-2 family proteins. J Biomol Screening 2014, 19:1201-1211.
143. Moffat J.G., Rudolph J., Bailey D. Phenotypic screening in cancer drug discovery - past, present and future. Nat Rev Drug Discov 2014, 13:588-602.
144. Eder J., Sedrani R., Wiesmann C. The discovery of first-in-class drugs: origins and evolution. Nat Rev Drug Discov 2014, 13:577-587.
145. Swinney D.C., Anthony J. How were new medicines discovered?. Nat Rev Drug Discov 2011, 10:507-519.
146. Lee A.Y., St Onge R.P., Proctor M.J., Wallace I.M., Nile A.H., Spagnuolo P.A., et al. Mapping the cellular response to small molecules using chemogenomic fitness signatures. Science 2014, 344:208-211.
147. Mohr S.E., Smith J.A., Shamu C.E., Neumuller R.A., Perrimon N. RNAi screening comes of age: improved techniques and complementary approaches. Nat Rev Mol Cell Biol 2014, 15:591-600.
148. Marston A., Hostettmann K. Modern separation methods. Nat Prod Rep 1991, 8:391-413.
149. Hostettmann K., Wolfender J.-L., Rodriguez S. Rapid detection and subsequent isolation of bioactive constituents of crude plant extracts. Planta Med 1997, 63:2-10.
150. Jaki B., Franzblau S., Pauli G.F. An N.M.R. method towards the routine chiral determination of natural products. Phytochem Anal 2004, 15:213-219.
151. Gronquist M., Meinwald J., Eisner T., Schroeder F.C. Exploring uncharted terrain in Nature's structure space using capillary NMR spectroscopy: 13 steroids from 50 fireflies. J Am Chem Soc 2005, 127:10810-10811.
152. Wolfender J.L., Queiroz E.F., Hostettmann K. Phytochemistry in the microgram domain - a LC-NMR perspective. Mag Res Chem 2005, 43:697-709.
153. Konishi Y., Kiyota T., Draghici C., Gao J.M., Yeboah F., Acoca S., et al. Molecular formula analysis by an MS/MS/MS technique to expedite dereplication of natural products. Anal Chem 2007, 79:1187-1197.
154. Lambert M., Wolfender J.L., Staerk D., Christensen B., Hostettmann K., Jaroszewski J.W. Identification of natural products using HPLC-SPE combined with CapNMR. Anal Chem 2007, 79:727-735.
155. Queiroz E.F., Wolfender J.L., Hostettmann K. Modern approaches in the search for new lead antiparasitic compounds from higher plants. Curr Drug Targ 2009, 10:202-211.
156. Friesen J.B., Pauli G.F. G.U.E.S.S. - A generally useful estimate of solvent systems for CCC. J Liq Chromatog RelTechnol 2005, 28:2777-2806.
157. Simmler C., Napolitano J.G., McAlpine J.B., Chen S.N., Pauli G.F. Universal quantitative NMR analysis of complex natural samples. Curr Opin Biotechnol 2014, 25:51-59.
158. El-Elimat T., Figueroa M., Ehrmann B.M., Cech N.B., Pearce C.J., Oberlies N.H., et al. High-resolution MS, MS/MS, and UV database of fungal secondary metabolitees as a dereplicatoin protocol for bioactive natural products. J Nat Prod 2013, 76:1709-1716.
159. Bouslimani A., Sanchez L.M., Garg N., Dorrenstein P.C. Mass spectrometry of natural products: current, emerging and future technologies. Nat Prod Rep 2014, 31:718-729.
160. Mohimani H., Liu W.-T., Kersten R.D., Moore B.S., Dorrestein P.C., Pevzner P.A. NRPquest: coupling mass spectrometry and genome mining for nonribosomal peptide discovery. J Nat Prod 2014, 77:1902-1909.
161. Cragg G.M., Schepartz S.A., Suffness M., Grever M.R. The taxol supply crisis. New NCI policies for handling the large-scale production of novel natural product anticancer and anti-HIV agents. J Nat Prod 1993, 56:1657-1668.
162. Fujita Y. Industrial production of shikonin and berberine. Applications of plant cell and tissue culture 1988, 157-174. Wiley, Chichester. G. Bock, J. Marsh (Eds.).
163. Fowler M.W., Cresswell R.C., Stafford A.M. An economic and technical assessment of the use of plant cell cultures for natural product synthesis on an industrial scale. Bioactive compounds from plants 1990, 228-238. Wiley, Chichester. D.J. Chadwick, J. Marsh (Eds.).
164. Kingston D.G.I Taxol and its analogs. Anticancer agents from natural products 2012, 123-175. CRC Press/Taylor and Francis, Boca Raton, FL. 2nd ed. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
165. Hayden A.L., Giacomelli G.A., Hoffmann J.J., Yokelson T.N. Aeroponics: an alternative production system for high-value root crops. Acta Horticulturae 2004, 629:207-213.
166. Hayden A.L. Aeroponic and hydroponic systems for medicinal herb, rhizome, and root crops. HortScience 2006, 41:536-538.
167. Xu Y.M., Gao S., Bunting D.P., Gunatilaka A.A.L. Unusual withanolides from aeroponically grown Withania somnifera. Phytochemistry 2011, 72:518-522.
168. Mickel S.J., Niederer D., Daeffler R., Osmani A., Kuesters E., Schmid E., et al. Large-scale synthesis of the anti-cancer marine natural product (+)-discodermolide. Part 5: linkage of fragments C1-6 and C7-24 and finale. Org Process Res Dev 2004, 8:122-130.
169. Yu M.J., Kishi Y., Littlefield B.A. Discovery of E7389: a fully synthetic macrocyclic ketone analog of halichondrin B. Anticancer agents from natural products 2012, 317-345. CRC Press/Taylor and Francis, Boca Raton, FL. 2nd ed. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
170. Cragg G.M., Grothaus P.G., Newman D.J. Impact of natural products on developing new anti-cancer agents. Chem Rev 2009, 109:3012-3043.
171. Liu J., Hu Y., Waller D.L., Wang J., Liu Q. Natural products as kinase inhibitors. Nat Prod Rep 2012, 29:392-403.
172. Coxon G.D., Cooper C.B., Gillespie S.H., McHugh T.D. Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery. J Infect Dis 2012, 205:S258-S264.
173. Gross F., Lazar J., Orth H. Inhibition of the renin-angiotensinogen reaction by pepstatin. Science 1972, 175:656.
174. Darke P.L., Leu C.-T., Davis L.J., Heimbach J.C., Diehl R.E., Hill W.S., et al. Human immunodeficiency virus protease. Bacterial expression and characterization of the purified aspartic protease. J Biol Chem 1989, 264:2307-2312.
175. Evans B.E., Rittle K.E., Homnick C.F., Springer J.P., Hirshfield J., Veber D.F. A stereocontrolled synthesis of hydroxyethylene dipeptide isosteres using novel, chiral aminoalkyl epoxides and .gamma.-(aminoalkyl)-.gamma.-lactones. J Org Chem 1985, 50:4615-4625.
176. DeSolms S.J., Giuliani E.A., Guare J.P., Vacca J.P., Sanders W.M., Graham S.L., et al. Design and synthesis of HIV protease inhibitors. Variations of the carboxyterminus of the HIV protease inhibitor L-682,679. J Med Chem 1991, 34:2852-2857.
177. Ripka A.S., Rich D.H. Peptidomimetic design. Curr Opin Chem Biol 1998, 4:439-452.
178. Schechter I., Berger A. On the size of the active site of proteases. I. Papain. Biochem Biophys Res Commun 1967, 27:157-162.
179. Rahuel J., Rasetti V., Maibaum J., Rueger H., Goschke R., Cohen N.-C., et al. Structure-based drug design: the discovery of novel non-peptide orally active inhibitors of human renin. Chem Biol 2000, 7:493-504.
180. Wood J.M., Maibaum J., Rahuel J., Grutter M.G., Cohen N.-C., Rasetti V., et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003, 308:698-705.
181. Stassen J.A., Li Y., Richart T. Oral renin inhibitors. Lancet 2006, 368:1449-1456.
182. Webb R.L., Schiering N., Sedrani R., Maibaum J. Direct renin inhibiotrs as a new therapy for hypertension. J Med Chem 2010, 53:7490-7520.
183. Politi A., Leonis G., Tzoupis H., Ntountaniotis D., Papadopoulos M.G., Grdadolnik S.G., et al. Conformational properties and energetic analysis of aliskiren. Mol Inf 2011, 30:973-985.
184. Tzoupis H., Leonis G., Megariotis G., Supuran C.T., Mavromoustakos T., Papadopoulos M.G. Dual inhibitors for aspartic proteases HIV-1 PR and Renin: advancements in AIDS-hypertension-diabetes via molecular dynamics, inhibition assays, and binding free energy calculations. J Med Chem 2012, 55:5784-5796.
185. Nam G., Ko S.Y. A total synthesis of aliskiren. Helv Chim Acta 2012, 95:1937-1945.
186. Ehara T., Irie O., Kosaka T., Kanazawa T., Breitenstein W., Grosche P., et al. Structure-based design of substituted piperidines as a new class of highly efficacious oral direct renin inhibitors. ACS Med Chem Lett 2014, 5:787-792.
187. Palomo J.M. Solid-phase peptide synthesis: an overview focused on the preparation of biologically relevant peptides. RSC Adv 2014, 4:32658-32672.
188. Momi S., Impagnatiello F., Guzzetta M., Caracchini R., Guglielmini G., Olivieri R., et al. NCX 6560: a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. Eur J Pharmacol 2007, 570:115-124.
189. Baetta R., Granata A., Miglietta D., Oliva F., Arnaboldi L., Bonomo A., et al. Nitric oxide-donating atorvastatin attenuates neutrophil recruitment during vascular inflammation independent of changes in plasma cholesterol. Cardiovasc Drugs Ther 2013, 27:211-219.
190. Oslaj M., Cluzeau J., Orkic D., Kopitar G., Mrak P., Casar Z. A highly productive, whole cell DERA chemoenzymatic process for production of key lactonized side-chain intermediates in statin synthesis. PLoS one 2013, 8:e62250.
191. Vajdic T., Oslaj M., Kopitar G., Mrak P. Engineered, highly productive biosynthesis of artificial, lactonized statin side-chain building blocks: the hidden potential of Escherichia coli unleashed. Metab Eng 2014, 24:160-172.
192. McIntyre J.A., Castaner J. ISA-247 - Calcineurin inhibitor treatment of renal transplant rejection treatment of psoriasis. Drugs Future 2004, 29:680-686.
193. Maeng J.H., Yang Z.C., Manning D.D., Masih L., Cao Y.Y., Pattamana K.G., et al. Organozirconium chemistry on cyclosporin: a novel process for the highly stereoselective synthesis of (E)-ISA247 (Voclosporin) and close analogues. Synthesis 2012, 44:63-68.
194. Adachi K., Kohara T., Nakao N., Arita M., Chiba K., Mishina T., et al. Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols - discovery of a novel immunosuppressant, FTY720. Bioorg Med Chem Lett 1995, 5:853-856.
195. Strader C.R., Pearce C.J., Oberlies N.H. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. J Nat Prod 2011, 74:900-907.
196. Zhang L., Wang H.D., Ji X.J., Cong Z.X., Zhu J.H., Zhou Y. FTY720 for cancer therapy (Review). Oncol Rep 2013, 30:2571-2578.
197. Takasugi N, Sasaki T, Ebinuma I, Osawa S, Isshiki H, Takeo K, et al. FTY720/Fingolimod, a sphingosine analogue, reduces amyloid-beta production in neurons.
198. Martin R., Mireia S. Sphingosine-1 phosphate and central nervous system. Sphingosine-1-phosphate signaling in immunology and infectious diseases 2014, 2014:149-170. Springer International Publishing, Switzerland.
199. Zhou R., Zhang F., He P.L., Zhou W.L., Wu Q.L., Xu J.Y., et al. (5R)-5-hydroxytriptolide (LLDT-8), a novel triptolide analog mediates immunosuppressive effects in vitro and in vivo. Int Immunopharmacol 2005, 5:1895-1903.
200. Tang W., Zuo J.P. Immunosuppressant discovery from Tripterygium wilfordii Hook f: the novel triptolide analog (5R)-5-hydroxytriptolide (LLDT-8). Acta Pharmacol Sin 2012, 33:1112-1118.
201. Bohuslavizki K.H., Hinck-Kneip C., Kniep A., Koppenhofer E., Reimers A. Reduction of MS-related scotoma by new class of potassium channel blockers from Ruta graveolens. Neuroopthalmol 1993, 13:191-198.
202. Bohuslavizki K.H., Hansel W., Kniep A., Koppenhofer E., Niemoller K., Sanmann K. Mode of action of psoralens, benzofurans, acridones and coumarins on the ionic currents in intact myelinated nerve firbres and its significance in demyelating diseases. Gen Physiol Biophys 1994, 13:309-328.
203. Schmitz A., Sankaranarayanan A., Azam P., Schmidt-Lassen K., Homerick D., Hänsel W., et al. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol 2005, 68:1254-1270.
204. Beeton C., Wulff H., Standifer N.E., Azam P., Mullen K.M., Pennington M.W., et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci U S A 2006, 103:17414-17419.
205. Payne D.J., Gwynn M.N., Holmes D.J., Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007, 6:29-40.
206. Revill P., Serradell N., Bolos J., Tiacumicin B. Macrolide antibiotic, treatment of C difficile-associated diarrhea. Drugs Future 2006, 31:494-497.
207. Leadbetter M.R., Adams S.M., Bazzini B., Fatheree P.R., Karr D.E., Krause K.M., et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot 2004, 57:326-336.
208. Malabarba A., Ciabatti R., Scotti R., Goldstein B.P., Ferrari P., Kurz M., et al. New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci. J Antibiot 1995, 48:869-883.
209. Economou N.J., Nahoum V., Weeks S.D., Grasty K.C., Zentner I.J., Townsend T.M., et al. A carrier protein strategy yields the structure of dalbavancin. J Am Chem Soc 2012, 134:4637-4645.
210. Cooper R.D., Snyder N.J., Zweifel M.J., Staszak M.A., Wilkie S.C., Nicas T.I., et al. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J Antibiot 1996, 49:575-581.
211. Liapikou A., Torres A. Emerging drugs on methicillin-resistant Staphylococcus aureus. Exp Opin Emerg Drugs 2013, 18:291-305.
212. Chou T.-C., Zhang X., Zhong Z.-Y., Li Y., Feng L., Eng S., et al. Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones. Proc Natl Acad Sci U S A 2008, 105:13157-13162.
213. Wilson R.M., Danishefsky S.J. On the reach of chemical synthesis: creation of a mini-pipeline from an academic laboratory. Angew Chem Int Ed 2010, 49:6032-6056.
214. Altmann K.-H., Schinzer D. Chemistry and biology of epothilones. Natural products in medicinal chemistry 2014, 83-125. Wiley-VCH Verlag, Weinheim, Germany. S. Hanessian (Ed.).
215. Gao J., Hamann M.T. Chemistry and biology of kahalalides. Chem Rev 2011, 111:3208-3235.
216. Rath C.M., Janto B., Earl J., Ahmed A., Hu F.Z., Hiller L., et al. Meta-omic characterization of the marine Invertebrate microbial consortium that produces the chemotherapeutic natural product ET-743. ACS Chem Biol 2011, 6:1244-1256.
217. Wani M.C., Taylor H.L., Wall M.E., Coggon P., McPhail A.T. Plant antitumor agents. VI. The Isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971, 93:2325-2327.
218. Schiff P.B., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277:665-667.
219. Suffness M. Taxol: from discovery to therapeutic use. Ann Rep Med Chem 1993, 305-314. Academic Press, Academic Press, San Diego. J.A. Bristol (Ed.).
220. Jacoby M. The top pharmaceuticals that changed the world. C&E News 2005;83:(25), 120.
221. Wang X., Itokawa H., Lee K.-H. Structure-activity relationships of taxoids. Taxus: the genus taxus 2003, Taylor & Francis, London, p. 298-86. H. Itokawa, K.-H. Lee (Eds.).
222. Cragg G.M., Newman D.J. A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. J Nat Prod 2004, 67:232-244.
223. Dubois J. Recent progress in the development of docetaxel and paclitaxel analogues. Expert Opin Ther Patents 2006, 16:1481-1496.
224. Kingston D.G.I., Newman D.J. Taxoids: cancer-fighting compounds from nature. Curr Opin Drug Disc Devel 2007, 10:130-144.
225. Ojima I., Kamath A., Seitz J.D. Taxol, taxoids, and related taxanes. Natural products in medicinal chemistry 2014, 127-180. Wiley-VCH Verlag, Weinheim, Germany. S. Hanessian (Ed.).
226. Guenard D., Gueritte-Voegelein F., Potier P. Taxol and taxotere: discovery, chemistry, and structure-activity relationships. Acc Chem Res 1993, 26:160-167.
227. Green M.R., Manikhas G.M., Orlov S., Afanasyev B., Makhson A.M., Bhar P., et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006, 17:1263-1268.
228. Galsky M.D., Dritselis A., Kirkpatrick P., Oh W.K. Cabazitaxel. Nat Rev Drug Disc 2010, 9:677-678.
229. Bouchard H., Semiond D., Risse M.-L., Vrignaud P. Novel taxanes: cabazitaxel case study. Analogue-based drug discovery III 2013, 319-341. Wiley-VCH Verlag, Weinheim, Germany. J. Fischer, C.R. Ganellin, D.P. Rotella (Eds.).
230. Sternberg C.N., Skoneczna I.A., Castellano D., Theodore C., Blais N., Voog E., et al. Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB). Oncology 2013, 85:208-215.
231. Beer M., Lenaz L., Amadori D. Phase II study of ortataxel in taxane-resistant breast cancer. J Clin Oncol 2008, 26. Abstract 1066.
232. Kato K., Chin K., Yoshikawa T., Yamaguchi K., Tsuji Y., Esaki T., et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest New Drugs 2012, 30:1621-1627.
233. Paz-Ares L., Ross H., O'Brien M., Riviere A., Gatzemeier U., Von Pawel J., et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer 2008, 98:1608-1613.
234. Hartwell J.L., Schrecker A.W. Chemistry of podophyllum. Fortschritte chemie der organische naturstoffe [Progress in the chemistry of organic natural products] 1958, 1958:83-166. Springer-Verlag, Vienna, [in German].
235. Stahelin H.F., von Wartburg A. The chemical and biological route from podophyllotoxin glucoside to etoposide: ninth cain memorial award lecture. Cancer Res 1991, 51:5-15.
236. Hande K.R. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998, 34:1514-1521.
237. Lee K.-H., Xiao Z. Podophyllotoxin and analogs. Anticancer agents from natural products 2012, 95-122. CRC Press, Boca Raton, FL. 2nd ed. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
238. Noble R.L., Beer C.T., Cutts J.H. Role of chance observation in chemotherapy: vinca rosea. Ann NY Acad Sci 1958, 76:882-894.
239. Dancey J., Steward W.P. The role of vindesine in oncology: recommendations after 10 years' experience. Anti-Cancer Drugs 1995, 6:625-636.
240. Bellmunt J., Fougeray R., Rosenberg J.E., von der Maase H., Schutz F.A., Salhi Y., et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol 2013, 24:1466-1472.
241. Gueritte F., Fahy J. The vinca alkaloids. Anticancer agents from natural products 2012, 177-198. CRC Press, Boca Raton, FL. 2nd ed. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
242. Wall M.E. Camptothecin and taxol: discovery to clinic. Med Res Rev 1998, 18:299-314.
243. Rahier N.J., Thomas C.J., Hecht S.M. Camptothecin and its analogs. Anticancer agents from natural products 2012, 5-25. CRC Press, Boca Raton, FL. 2nd ed. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
244. Giannini G. Camptothecin and Analogs. Natural products in medicinal chemistry 2014, 181-224. Wiley-VCH Verlag, Weinheim, Germany. S. Hanessian (Ed.).
245. Gras J. Ingenol mebutate: a new option for actinic keratosis treatment. Drugs Today 2013, 49:15-22.
246. Itokawa H., Hitotsuyanagi Y., Lee K.-H. Homoharringtonine and related compounds. Anticancer agents from natural products 2012, 65-93. CRC Press, Boca Raton, FL. 2nd ed. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
247. Gandhi V., Plunkett W., Cortes J.E. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res 2014, 20:1735-1740.
248. Pinney K.G., Pettit G.R., Trawick M.L., Jelinek C., Chaplin D.J. The discovery and development of the combretastatins. Anticancer agents from natural products 2012, 27-63. CRC Press, Boca Raton, FL. 2nd ed. G.M. Cragg, D.G.I. Kingston, D.J. Newman (Eds.).
249. Nagaiah G., Remick S.C. Combretastatin A4 phosphate: a novel vascular disrupting agent. Future Oncol 2010, 6:1219-1228.
250. Hirata Y., Uemura D. Halichondrins - antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986, 58:701-710.
251. Pettit G.R., Herald C.L., Boyd M.R., Leet J.E., Dufresne C., Doubek D.L., et al. Antineoplastic agents. 219. Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J Med Chem 1991, 34:3339-3340.
252. Choi H.-W., Demeke D., Kang F.-A., Kishi Y., Nakajima K., Nowak P., et al. Synthetic studies on the marine natural product halichondrins. Pure Appl Chem 2003, 75:1-17.
253. Zheng W., Seletsky B.M., Palme M.H., Lydon P.J., Singer L.A., Chase C.E., et al. Macrocyclic ketone analogues of halichondrin B. Bioorg Med Chem Lett 2004, 14:5551-5554.
254. Yu M.J., Zheng W., Seletsky B.M. From micrograms to grams: scale-up synthesis of eribulin mesylate. Nat Prod Rep 2013, 30:1158-1164.
255. Chase C.E., Fang F.G., Lewis B.M., Wilke G.D., Schnaderbeck M.J., Zhu X. Process development of halaven®: synthesis of the C1-C13 fragment from d -(-)-gulono-1,4-lactone. Synlett 2013, 24:323-326.
256. Austad B.C., Benayoud F., Calkins T.L., Campagnaa S., Chase C.E., Choi H.-W., et al. Process development of halaven®: synthesis of the C14-C35 fragment via iterative Nozaki-Hiyama-Kishi reaction-Williamson ether cyclization. Synlett 2013, 24:327-332.
257. Austad B.C., Calkins T.L., Chase C.E., Fang F.G., Horstmann T.E., Hu Y., et al. Commercial manufacture of halaven®: chemoselective transformations en route to structurally complex macrocyclic ketones. Synlett 2013, 24:333-337.
258. Negi A.S., Gupta A., Hamid A.A. Combating malaria with plant molecules: a brief update. Curr Med Chem 2014, 21:458-500.
259. Wongsrichanalai C., Pickard A.L., Wernsdorfer W.H., Meshnick S.R. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002, 2:209-218.
260. Klayman D.L. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985, 228:1049-1055.
261. Dondorp A.M., Nosten F., Yi P., Das D., Phyo A.P., Tarning J., et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009, 361:455-467.
262. Shandilya A., Chacko S., Jayaram B., Ghosh I. A plausible mechanism for the antimalarial activity of artemisinin: a computational approach. Sci Rep 2013, 3:2513.
263. Paddon C.J., Westfall P.J., Pitera D.J., Benjamin K., Fisher K., McPhee D., et al. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 2013, 496:528-532.
264. Chen H.-J., Han W.-B., Hao H.-D., Wu Y. A facile and scalable synthesis of qinghaosu (artemisinin). Tetrahedron 2013, 69:1112-1114.
265. Turconi J., Griolet F., Guevel R., Oddon G., Villa R., Geatti A., et al. Semisynthetic artemisinin, the chemical path to industrial production. Org Proc Res Dev 2014, 18:417-422.
266. Krishna S., Bustamante L., Haynes R.K., Staines H.M. Artemisinins: their growing importance in medicine. Trends Pharmacol Sci 2008, 29:520-527.
267. Mott B.T., Tripathi A., Siegler M.A., Moore C.D., Sullivan D.J., Posner G.H. Synthesis and antimalarial efficacy of two-carbon-linked, artemisinin-derived trioxane dimers in combination with known antimalarial drugs. J Med Chem 2013, 56:2630-2641.
268. Wright C.W. Recent developments in research on terrestrial plants used for the treatment of malaria. Nat Prod Rep 2010, 27:961-968.
269. Nogueira C.R., Lopes L.M.X. Antiplasmodial natural products. Molecules 2011, 16:2146-2190.
270. Kingston D.G.I., Newman D.J. Natural products as anticancer agents. Natural products in chemical biology 2012, 325-349. Wiley, New York. N. Civjan (Ed.).
271. Rohena C.C., Mooberry S.L. Recent progress with microtubule stabilizers: new compounds, binding modes, and cellular activities. Nat Prod Rep 2014, 31:335-355.
272. Basmadjian C., Zhao Q., Bentouhami E., Djehal A., Nebigil C.G., Johnson R.A., et al. Cancer wars: natural products strike back. Front Chem 2014, 2:1-18.
273. Nicolaou K.C., Roschangar F., Vourloumis D. Chemical biology of epothilones. Angew Chem Int Ed 1998, 37:2014-2045.
274. Evans B.E., Rittle K.E., Bock M.G., DiPardo R.M., Fredinger R.M., Whitter W.L., et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem 1988, 2235-2246.
275. Nicolaou K.C., Pfefferkorn J.A., Roecker A.J., Cao G.Q., Barluenga S., Mitchell H.J. Natural product-like combinatorial libraries based on privileged structures. 1. General principles and solid-phase synthesis of benzopyrans. J Am Chem Soc 2000, 122:9939-9953.
276. Nicolaou K.C., Pfefferkorn J.A., Mitchell H.J., Roecker A.J., Barluenga S., Cao G.Q., et al. Natural product-like combinatorial libraries based on privileged structures. 2. Construction of a 10,000-membered benzopyran library by directed split-and-pool chemistry using NanoKans and optical encoding. J Am Chem Soc 2000, 122:9954-9967.
277. Nicolaou K.C., Pfefferkorn J.A., Barluenga S., Mitchell H.J., Roecker A.J., Cao G.-Q. Natural product-like combinatorial libraries based on privileged structures. 3. The "libraries from libraries" principle for diversity enhancement of benzopyran libraries. J Am Chem Soc 2000, 122:9968-9976.
278. Nicolaou K.C., Cao G.Q., Pfefferkorn J.A. Selenium-based solid-phase synthesis of benzopyrans II: applications to combinatorial synthesis of medicinally relevant small organic molecules. Angew Chem Int Ed 2000, 39:739-743.
279. Breinbauer R., Vetter I.R., Waldmann H. From protein domains to drug candidates: natural products as guiding principles in the design and synthesis of compound libraries. Angew Chem Int Ed 2002, 41:2878-2890.
280. Koch M.A., Waldmann H. Protein structure similarity clustering and natural product structure as guiding principles in drug discovery. Drug Discov Today 2005, 10:471-483.
281. Van Hattum H., Waldmann H. Biology-oriented synthesis: harnessing the power of evolution. J Am Chem Soc 2014, 136:11853-11859.
282. Wetzel S., Bon R.S., Kumar K., Waldmann H. Biology-oriented synthesis. Angew Chem Int Ed 2011, 50:10800-10826.
283. McArdle B.M., Campitelli M.R., Quinn R.J. A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets. J Nat Prod 2006, 69:14-17.
284. Newman D.J. Natural products as leads to potential drugs: an old process or the new hope for drug discovery?. J Med Chem 2008, 51:2589-2599.
285. Burke M.D., Berger E.M., Schreiber S.L. Generating diverse skeletons of small molecules combinatorially. Science 2003, 302:613-618.
286. Burke M.D., Schreiber S.L. A planning strategy for diversity-oriented synthesis. Angew Chem Int Ed 2004, 43:46-58.
287. Schreiber S.L. Molecular diversity by design. Nature 2009, 457:153-154.
288. Natural products: discourse, diversity, and design 2014, Wiley Blackwell, Oxford, UK. A. Osbourn, R.J.M. Goss, G.T. Carter (Eds.).
289. Graziani E.I. ILS-920: a rapamycin analog for ischemic stroke. Natural products: discourse, diversity, and design 2014, 469-481. Wiley Blackwell, Oxford, UK. A. Osbourn, R.J.M. Goss, G.T. Carter (Eds.).
290. Gregory M.A., Moss S.J., Wilkinson B. BC265: a nonquinone ansamycin HSP90 inhibitor developed using biosynthetic medicinal chemistry. Natural products: discourse, diversity, and design 2014, 2014:483-496. Wiley Blackwell, Oxford, UK.
291. Martin C.J., Gaisser S., Challis I.R., Carletti I., Wilkinson B., Gregory M., et al. Molecular characterization of macbecin as an Hsp90 inhibitor. J Med Chem 2008, 51:2853-2857.
292. Zhang M.-Q., Gaisser S., Nur-E-Alam M., Sheehan L.S., Vousden W.A., Gaitatzis N., et al. Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors. J Med Chem 2008, 51:5494-5497.
293. Wishart D.S. Applications of metabolomics in drug discovery and development. Drugs R D 2008, 9:307-332.
294. Hou Y., Braun D.R., Michel C.R., Klassen J.L., Adnani N., Wyche T.P., et al. Microbial strain prioritization using metabolomics tools for the discovery of natural products. Anal Chem 2012, 84:4277-4283.
295. Tawfike A.F., Viegelmann C., Edrada-Ebel R. Metabolomics and dereplication strategies in natural products. Methods Mol Biol 2013, 1055:227-244.
296. Yuliana N.D., Janhangir M., Verpoorte R., Choi Y.H. Metabolomics for the rapid dereplication of bioactive compounds from natural sources. Phytochem Rev 2013, 12:293-304.
297. Krug D., Müller R. Secondary metabolomics: the impact of mass spectrometry-based approaches on the discovery and characterization of microbial natural products. Nat Prod Rep 2014, 31:768-783.
298. Charlop-Powers Z., Milshteyn A., Brady S.F. Metagenomic small molecule discovery methods. Curr Opin Microbiol 2014, 19:70-75.
299. Aldridge B.A., Rhee K.Y. Microbial metabolomics: innovation, application, insight. Curr Opin Microbiol 2014, 19:90-96.
300. Donia M.S., Cimermancic P., Schulze C.J., Wieland Brown L.C., Martin J., Mitreva M., et al. A systematic analysis of biosynthetic gene clusters in the human microbiome reveals a common family of antibiotics. Cell 2014, 158:1402-1414.
301. Vence T. Mining microbes for promising therapies: warp Drive Bio has industrialized its genomics platform in its hunt for natural products. Gen Eng Biotech News 2013 2013, 33:12-14.